CN104250225A - Atazanavir phosphate and its preparation method and use - Google Patents
Atazanavir phosphate and its preparation method and use Download PDFInfo
- Publication number
- CN104250225A CN104250225A CN201310269882.7A CN201310269882A CN104250225A CN 104250225 A CN104250225 A CN 104250225A CN 201310269882 A CN201310269882 A CN 201310269882A CN 104250225 A CN104250225 A CN 104250225A
- Authority
- CN
- China
- Prior art keywords
- reyataz
- crystal formation
- phosphatic crystal
- phosphatic
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses atazanavir phosphate and its preparation method and use. The crystal form of atazanavir phosphate can be characterized by a XRD spectrogram and a DSC trace. The preparation method comprises the following steps of 1, mixing atazanavir free alkali and a polar solvent and heating the mixture for promoting dissolution, 2, adding phosphoric acid into the solution so that the atazanavir free alkali forms a salt, and carrying out thermal insulation, and 3, separating the salt obtained by the step 2 so that the crystal form of atazanavir phosphate can be obtained. The crystal form of atazanavir phosphate has good crystal stability and solubility, can be prepared by simple processes, has high practicality and can be used as a HIV protease inhibitor for HIV infection treatment based on combination with other retrovirus-resistant drugs.
Description
Technical field
The present invention relates to acid salt of a kind of novel Reyataz R and preparation method thereof, particularly relate to a kind of Reyataz R phosphoric acid salt and Synthesis and applications thereof.
Background technology
Reyataz R (Atazanavir) has such as formula the chemical structure shown in I; chemistry 1-[4-(pyridine-2-base) phenyl]-5 (S)-2,5-bis-{ [the tertiary leucyl of N-(methoxycarbonyl)-L-] is amino } by name-4-(S)-hydroxyl-6-phenyl-2-aza-hexane.Reyataz R is disclosed in US5849911A, its hydrosulfate obtained FDA approval for treating HIV virus infection with other antiretroviral drugs couplings in 2003, with trade(brand)name REYATAZ(Bristol-Myers Squibb) capsule form sell, the hydrosulfate of Reyataz R is disclosed in US6087383A.
As the acid salt of Reyataz R, except above-mentioned patent discloses its hydrosulfate, also in the embodiment of US5849911A, disclose its hydrochloride, and in addition, also there is not specifically known acid salt.As the crystal formation of the acid salt of Reyataz R, patent US6087383A describes Zrivada I N-type waferN (anhydrous desolvation crystal formation) and II N-type waferN (hydrated hygroscopic crystal formation) in an embodiment, WO2005108349A2 discloses C mode material and the E3 N-type waferN (three alcohol solvent crystal formations) of Zrivada, and in addition, also there is not the stable crystal form of specifically known acid salt.
Therefore, on the basis studied hydrosulfate and the hydrochloride of Reyataz R, thirst for finding that other have the acid salt of the Reyataz R of better crystal stability and solubleness.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of novel Reyataz R phosphoric acid salt and Synthesis and applications thereof.Novel Reyataz R phosphoric acid salt of the present invention has good crystalline stability, and preparation method is simple, and can be used as the use of hiv protease inhibitor.
For solving the problems of the technologies described above, novel Reyataz R phosphoric acid salt of the present invention, a kind of crystal Reyataz R phosphoric acid salt, the phosphatic crystal formation of this Reyataz R characterizes by the X-ray diffraction pattern comprising two or more X-ray diffraction peak, wherein, described two or more X-ray diffraction peak, be selected from 6.74 °, 6.63 °, 7.60 °, 8.11 °, 10.40 °, 11.31 °, 11.77 °, 12.63 °, 13.72 °, 15.45 °, 16.42 °, 17.19 °, 17.90 °, 18.39 °, 19.01 °, 19.44 °, 20.23 °, 20.61 °, 21.87 °, 22.58 °, 23.79 °, 25.56 °, 28.53 °, 29.06 °, 31.18 °, 33.14 °, the X-ray diffraction peak that 36.54 ° and 39.06 ° ± 0.2 ° 2 θ have.
The phosphatic crystal formation of described Reyataz R, has X-ray diffractogram as shown in Figure 2 substantially.
The phosphatic crystal formation of described Reyataz R, also by DSC(differential scanning calorimetry, dsc) trace characterizes, described DSC trace is included in 154.69 ~ 170.36(as 156.69 ± 2 ~ 168.36 ± 2) DEG C and 184.36 ~ 197.33(as 186.36 ± 2 ~ 195.33 ± 2) endotherm(ic)peak at DEG C place.Preferably, described DSC trace is included in the endotherm(ic)peak at 164.65 ± 2 DEG C and 191.78 ± 2 DEG C places.In addition, described DSC trace is included in the enthalpy of phase change at 8.94 ± 2J/g and-10.00 ± 2J/g place.
The phosphatic crystal formation of described Reyataz R, has DSC trace as shown in Figure 3 substantially.
In addition, the invention also discloses the preparation method of the phosphatic crystal formation of above-mentioned novel Reyataz R, its route is as follows:
In this route, by when there being polar solvent by the Reyataz R free alkali of formula I, i.e. 1-[4-(pyridine-2-base) phenyl]-5 (S)-2, 5-bis-{ [the tertiary leucyl of N-(methoxycarbonyl)-L-] is amino }-4-(S)-hydroxyl-6-phenyl-2-aza-hexane and phosphatase reaction, formula I is converted into the Reyataz R phosphoric acid salt of corresponding formula II, i.e. 1-[4-(pyridine-2-base) phenyl]-5 (S)-2, 5-bis-{ [the tertiary leucyl of N-(methoxycarbonyl)-L-] is amino }-4-(S)-hydroxyl-6-phenyl-2-aza-hexane phosphoric acid salt.
For above-mentioned preparation method, specifically can comprise the following steps:
1) Reyataz R free alkali is mixed with polar solvent (being suspension after mixing), and heating promotes to dissolve;
2) add phosphoric acid, make Reyataz R free alkali salify, and be incubated;
3) separating step 2) salt that obtains, obtain the phosphatic crystal formation of Reyataz R.
In described step 1), polar solvent, comprising: one or more in single polar protic solvent, single polar aprotic solvent; Wherein, single polar protic solvent comprises: water, ethanol or Virahol; Single polar aprotic solvent comprises: acetone or butanone etc.; Preferably, polar solvent is selected from the volume ratio of mixed solution, butanone and the water that the volume ratio of acetone, butanone, acetone and water is 95:5 is the mixed solution of 95:5; The temperature of heating is 35 ~ 65 DEG C, and be preferably 55 DEG C, the time of heating can be 0.5 ~ 3 hour, is preferably 1 hour.
Described step 2) in, the consumption mol ratio of phosphoric acid and Reyataz R free alkali is 1 ~ 1.1:1, is preferably 1.05:1; The temperature of insulation is 35 ~ 65 DEG C, and soaking time is 0.5 ~ 3 hour, is preferably 1 hour.
In described step 3), separating step 2) method of salt that obtains comprises: directly crystallisation by cooling, add poor solvent crystallization or directly boil off solvent after recrystallization, filter, dry, obtain the phosphatic crystal formation of Reyataz R.Wherein, in direct crystallisation by cooling, by being down to room temperature and carrying out stirring realizing, the time of stirring is 0.5 ~ 4 hour, is preferably 1.5 hours; Poor solvent comprises: one or more in the tertiary ether of normal hexane, normal heptane, first.
Moreover, the invention also discloses the phosphatic crystal formation of above-mentioned novel Reyataz R and prepare the application in hiv protease inhibitor medicaments.
The invention also discloses a kind of pharmaceutical composition, it contains the phosphatic crystal formation of Reyataz R as above of significant quantity and pharmaceutically acceptable carrier.
Wherein, pharmaceutically acceptable carrier refers to the pharmaceutical carrier of pharmaceutical field routine, as water, starch, gelatin, spices, calcium carbonate, quaternary ammonium compound, cetyl alcohol, talcum powder etc.
This pharmaceutical composition can administration in a convenient way, as by the route of administration such as in local, intravenously, intramuscular, subcutaneous, intracutaneous, nose.
This pharmaceutical composition can adopt ordinary method to be prepared into corresponding preparations, as can be made into injection, tablet, capsule, etc. form.
The amount of the phosphatic crystal formation of novel Reyataz R in pharmaceutical composition of the present invention can change in the four corner that those skilled in the art are used.Usually, (wt%) note by weight percentage, containing the phosphatic crystal formation of novel Reyataz R accounting for total formulation and be about 0.1-99.5wt% in pharmaceutical composition (formulation), the ratio being preferably 0.5-95wt% exists.
The consumption of pharmaceutical composition of the present invention and the course for the treatment of can appropriately adjust according to the light and heavy degree of the age of formulation, patient, disease, namely concrete application dosage depends on many factors, as factors such as administering mode, medication person's healthy state, these are all in skilled practitioners skill.Specifically can be, about per daily dose is 0.01-10mg/kg body weight, and preferably about 0.1-5mg/kg body weight, can use by one or many.
The phosphatic crystal formation of Reyataz R of the present invention has good crystal stability and solubleness, and preparation process is simple, practical.Thus, this crystal formation also can be used as hiv protease inhibitor and HIV virus infection is treated in other antiretroviral drugs couplings.
Accompanying drawing explanation
Below in conjunction with accompanying drawing and embodiment, the present invention is further detailed explanation:
Fig. 1 is the DSC trace diagram of Reyataz R;
Fig. 2 is the X-ray diffractogram of the phosphatic crystal formation of Reyataz R;
Fig. 3 is the DSC trace diagram of the phosphatic crystal formation of Reyataz R.
Embodiment
The present invention is further illustrated below by embodiment.Mandatory declaration, following embodiment is for illustration of the present invention instead of limitation of the present invention.
In addition, the testing conditions of XRD, DSC and HPLC of relating in following examples can carry out according to as follows:
（1）DSC
Method one: be filled into by about 2mg sample in special aluminum sample dish, in a nitrogen atmosphere (50mL/min), test specification is 130 DEG C ~ 220 DEG C, and heat-up rate is 10 DEG C/min, METHOD FOR CONTINUOUS DETERMINATION, the thermal change produced between record sample and reference.
Method two: be filled into by about 2mg sample in special aluminum sample dish, in a nitrogen atmosphere (50mL/min), test specification is 30 DEG C ~ 300 DEG C, and heat-up rate is 10 DEG C/min, METHOD FOR CONTINUOUS DETERMINATION, the thermal change produced between record sample and reference.
（2）XRD
Sample is filled in special sample storage tank, measures, record the powder x-ray diffraction of sample under the following conditions.
Device: Bruker D8Advance XRD; Condition is as follows, radioactive source: Cu; Wavelength: 1.54056; Measurement range: 3.00 ~ 40.00 °; Sampling interval: 0.02 °; Sweep velocity: 3.00 °/min; Tube voltage: 40kV; Tube current: 40mA; Divergent slit: 1.0mm; Scatter slit: 0.6mm; Accept slit: 1.0mm.
（3）HPLC
Chromatographic instrument: Dionex U3000, DAD
Chromatographic column: C-18,4.6*250mm, 5 μm
Moving phase: volume ratio=70/30 of damping fluid/acetonitrile, wherein, damping fluid is: 1.36g potassium primary phosphate and 2.28g dipotassium hydrogen phosphate are dissolved in (0.02M) in 500ml water
Flow velocity: 1.0ml/min
Determined wavelength: 210nm
Sample size: 20 μ l
The preparation of the free state of reference example 1 Compound I
The method recorded according to patent US6087383A is prepared.
The Compound I prepared, the structural identification method through routine is also defined as Reyataz R, and wherein, the H-NMR collection of illustrative plates of this Compound I prepared is as follows:
1H?NMR(400MHz,CDCl
3):δ8.59(d,1H,J)0.8Hz),7.89–7.80(m,4H),7.51(d,1H,J)8.4Hz),7.37–7.32(m,1H),7.23–7.17(m,4H),7.15–7.10(m,1H),4.14(t,1H,J)7.2Hz),3.99(s,2H),3.84(s,1H),3.75(d,1H,J)9.6Hz),3.68(s,1H),3.63(s,3H),3.59(s,3H),2.96–2.82(m,3H),2.69(d,1H,J)12.9Hz),0.82(s,9H),0.71(s,9H)。
In addition, the differential scanning calorimetric thermogram feature of Reyataz R as shown in Figure 1, has heat absorption usually in the scope of about 208.22 DEG C to about 212.14 DEG C.
The preparation of the phosphatic crystal formation of embodiment 1 compound Reyataz R
With reference to Compound I (Reyataz R prepared by example 1,7.0g), acetone (50mL) joins in there-necked flask, be warmed up to 55 DEG C, disposablely add phosphate aqueous solution (1.3g85wt%(mass percent) phosphoric acid and 1.3g water, 1.1 equivalents), continue insulation 1h, slowly be down to room temperature, filter after stirring 1.5h, vacuum-drying, obtains the Reyataz R phosphoric acid salt (the phosphatic crystal formation of Reyataz R) of 6.8g white crystalline, yield: 85.3%, HPLC:99.1%, ee value (enantiomeric excess, enantiomeric excess) >=99.0%.
As shown in Figure 2, it the results are summarized in table 1 to the X-ray diffraction spectrogram of the phosphatic crystal formation of this Reyataz R prepared.
The list of table 1X ray diffraction peaks
Table 1 provides the phosphatic crystal formation of Reyataz R of embodiment 1 at 6.74 °, 6.63 °, 7.60 °, 8.11 °, 10.40 °, 11.31 °, 11.77 °, 12.63 °, 13.72 °, 15.45 °, 16.42 °, 17.19 °, 17.90 °, 18.39 °, 19.01 °, 19.44 °, 20.23 °, 20.61 °, 21.87 °, 22.58 °, 23.79 °, 25.56 °, 28.53 °, 29.06 °, 31.18 °, 33.14 °, there is corresponding diffraction peak the position at 2 θ places of 36.54 ° and 39.06 °.
Feature as shown in Figure 3 for the means of differential scanning calorimetry thermogram (DSC trace) of Reyataz R phosphatic crystal formation, in the scope of 156.69 DEG C ~ 168.36 DEG C and 186.87 DEG C ~ 195.33 DEG C, have heat absorption, and Fig. 3 additionally provides the DSC trace of crystal formation at the enthalpy of phase change at 8.94J/g and-10.00J/g place of the present embodiment 1.
The preparation of the phosphatic crystal formation of embodiment 2 compound Reyataz R
With reference to Compound I (Reyataz R prepared by example 1,7.1g), butanone (50mL) joins in there-necked flask, be warmed up to 35 DEG C, disposablely add phosphate aqueous solution (phosphoric acid of 1.2g85wt% and 1.2g water, 1.05 equivalent), continue insulation 0.5h, slowly be down to room temperature, filter after stirring 0.5h, vacuum-drying, obtains the Reyataz R phosphoric acid salt (the phosphatic crystal formation of Reyataz R) of 6.8g white crystalline, yield: 79.1%, HPLC:99.5%, ee value (enantiomeric excess, enantiomeric excess) >=99.2%.
The preparation of the phosphatic crystal formation of embodiment 3 compound Reyataz R
With reference to Compound I (Reyataz R prepared by example 1,7.5g), acetone (50mL) joins in there-necked flask, be warmed up to 65 DEG C, disposablely add phosphate aqueous solution (1.3g85wt% phosphoric acid and 1.1g water, 1.1 equivalents), continue insulation 2h, slowly be down to room temperature, filter after stirring 1h, vacuum-drying, obtains the phosphoric acid salt (the phosphatic crystal formation of Reyataz R) of the Reyataz R of 7.7g white crystalline, yield: 90.1%, HPLC:99.3%, ee value (enantiomeric excess, enantiomeric excess) >=99.2%.
The preparation of the phosphatic crystal formation of embodiment 4 compound Reyataz R
With reference to Compound I (Reyataz R prepared by example 1,7.5g), butanone (50mL) joins in there-necked flask, be warmed up to 45 DEG C, disposablely add phosphate aqueous solution (1.3g85wt% phosphoric acid and 1.1g water, 1.1 equivalents), continue insulation 3h, add normal hexane carry out crystallization or directly boil off solvent after recrystallization, filter, vacuum-drying, obtains the phosphoric acid salt (the phosphatic crystal formation of Reyataz R) of the Reyataz R of white crystalline.
X-ray diffraction spectrogram and the DSC trace of the crystal formation prepared in embodiment 2-4 are similar to embodiment 1.
Above experimental result shows, the phosphatic crystal formation of Reyataz R has good stability and solubleness, and preparation method is simple, can be used for treating HIV virus infection as hiv protease inhibitor and other antiretroviral drugs couplings.
Claims (11)
1. the phosphatic crystal formation of Reyataz R, it is characterized in that: characterized by the X-ray diffraction pattern comprising two or more X-ray diffraction peak, wherein, described two or more X-ray diffraction peak, be selected from 6.74 °, 6.63 °, 7.60 °, 8.11 °, 10.40 °, 11.31 °, 11.77 °, 12.63 °, 13.72 °, 15.45 °, 16.42 °, 17.19 °, 17.90 °, 18.39 °, 19.01 °, 19.44 °, 20.23 °, 20.61 °, 21.87 °, 22.58 °, 23.79 °, 25.56 °, 28.53 °, 29.06 °, 31.18 °, 33.14 °, the X-ray diffraction peak that 36.54 ° and 39.06 ° ± 0.2 ° 2 θ have.
2. the phosphatic crystal formation of Reyataz R as claimed in claim 1, is characterized in that: the phosphatic crystal formation of described Reyataz R has X-ray diffractogram as shown in Figure 2 substantially.
3. the phosphatic crystal formation of Reyataz R as claimed in claim 1, it is characterized in that: the phosphatic crystal formation of described Reyataz R is also characterized by DSC trace, wherein, DSC trace is included in the endotherm(ic)peak at 154.69 ~ 170.36 DEG C and 184.36 ~ 197.33 DEG C places.
4. the phosphatic crystal formation of Reyataz R as claimed in claim 3, is characterized in that: described DSC trace is included in the endotherm(ic)peak at 164.65 ± 2 DEG C and 191.78 ± 2 DEG C places.
5. the phosphatic crystal formation of Reyataz R as claimed in claim 1, it is characterized in that: the phosphatic crystal formation of described Reyataz R is also characterized by DSC trace, wherein, DSC trace is included in the enthalpy of phase change at 8.94 ± 2J/g and-10.00 ± 2J/g place.
6. the phosphatic crystal formation of Reyataz R as claimed in claim 5, is characterized in that: have DSC trace as shown in Figure 3 substantially.
7. a preparation method for the phosphatic crystal formation of the Reyataz R as described in any one of claim 1-6, is characterized in that, comprise the following steps:
1) Reyataz R free alkali is mixed with polar solvent, and heating promotes to dissolve;
2) add phosphoric acid, make Reyataz R free alkali salify, and be incubated;
3) separating step 2) salt that obtains, obtain the phosphatic crystal formation of Reyataz R.
8. method as claimed in claim 7, it is characterized in that: in described step 1), polar solvent, comprising: one or more in single polar protic solvent, single polar aprotic solvent; Wherein, single polar protic solvent comprises: water, ethanol or Virahol; Single polar aprotic solvent comprises: acetone or butanone; The temperature of heating is 35 ~ 65 DEG C;
Step 2) in, the consumption mol ratio of phosphoric acid and Reyataz R free alkali is 1 ~ 1.1:1; The temperature of insulation is 35 ~ 65 DEG C, and soaking time is 0.5 ~ 3 hour;
In step 3), separating step 2) method of salt that obtains comprises: directly crystallisation by cooling, add poor solvent crystallization or directly boil off solvent after recrystallization, filter, dry, obtain the phosphatic crystal formation of Reyataz R; Wherein, in direct crystallisation by cooling, by being down to room temperature and carrying out stirring realizing, the time of stirring is 0.5 ~ 4 hour; Poor solvent comprises: one or more in the tertiary ether of normal hexane, normal heptane, first.
9. method as claimed in claim 8, is characterized in that: in described step 1), and the volume ratio that polar solvent is selected from acetone, butanone, acetone and water is the mixed solution of 95:5, the volume ratio of butanone and water is the mixed solution of 95:5; The temperature of heating is 55 DEG C.
Step 2) in, the consumption mol ratio of phosphoric acid and Reyataz R free alkali is 1.05:1; Soaking time is 1 hour;
In step 3), the time of stirring is 1.5 hours.
10. the phosphatic crystal formation of the Reyataz R as described in any one of claim 1-6 is preparing the application in hiv protease inhibitor medicaments.
11. 1 kinds of pharmaceutical compositions, is characterized in that: the phosphatic crystal formation of the Reyataz R as described in any one of claim 1-6 containing significant quantity and pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269882.7A CN104250225A (en) | 2013-06-28 | 2013-06-28 | Atazanavir phosphate and its preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310269882.7A CN104250225A (en) | 2013-06-28 | 2013-06-28 | Atazanavir phosphate and its preparation method and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104250225A true CN104250225A (en) | 2014-12-31 |
Family
ID=52185507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310269882.7A Pending CN104250225A (en) | 2013-06-28 | 2013-06-28 | Atazanavir phosphate and its preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104250225A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109251165A (en) * | 2018-10-02 | 2019-01-22 | 黄胜利 | Atazanavir is up to two 4- amino phenyl sulfonyl hydrochlorates and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283188A (en) * | 1998-01-20 | 2001-02-07 | 布里斯托尔-米尔斯·斯奎布公司 | Bisulfate salt of HIV protease inhibitor |
-
2013
- 2013-06-28 CN CN201310269882.7A patent/CN104250225A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1283188A (en) * | 1998-01-20 | 2001-02-07 | 布里斯托尔-米尔斯·斯奎布公司 | Bisulfate salt of HIV protease inhibitor |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109251165A (en) * | 2018-10-02 | 2019-01-22 | 黄胜利 | Atazanavir is up to two 4- amino phenyl sulfonyl hydrochlorates and preparation method thereof |
| CN109251165B (en) * | 2018-10-02 | 2022-09-23 | 国药集团川抗制药有限公司 | Atazanavir darby 4-aminobenzenesulfonate and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101184734B (en) | Compound and methods of treating cell proliferation disorders | |
| CN104822680B (en) | Imidazopyridine | |
| JP6505013B2 (en) | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | |
| CN104109149B (en) | Deuterated diaminopyrimidine compounds and the pharmaceutical composition comprising the compound | |
| AU2017208215C1 (en) | Stable crystal form of tipiracil hydrochloride and crystallization method for the same | |
| NO335103B1 (en) | Compound, pharmaceutical composition containing the compound, use of the compound and method of preparation thereof | |
| AU2014295143B2 (en) | Salts of Dasatinib in amorphous form | |
| CN104903334A (en) | Tenofovir prodrug and pharmaceutical uses thereof | |
| JPWO2014017515A1 (en) | Crystalline polymorph of 4- [5- (pyridin-4-yl) -1H-1,2,4-triazol-3-yl] pyridine-2-carbonitrile and process for producing the same | |
| TW200306809A (en) | Compounds for the treatment of inflammatory disorders | |
| CN109863151A (en) | For treating the fused tricyclic pyridazinone compound of orthomyxovirus infection | |
| CN104955811A (en) | Deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing same | |
| AU2014295144B2 (en) | Salts of Dasatinib in crystalline form | |
| JP2020527166A (en) | N-Benzenesulfonylbenzamide compounds for inhibiting the Bcl-2 protein, their compositions and uses | |
| JP2021513982A (en) | P300 / CBP HAT Inhibitors and Methods of Their Use | |
| AU2016239028B2 (en) | P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor | |
| MX2015002310A (en) | Novel phenyl-pyridine/pyrazine amides for the treatment of cancer. | |
| TW200846338A (en) | Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof | |
| CN103613619A (en) | Preparation method of N-4-benzenesulfonamido-N'-1-deoxy-beta-D-pyran glucuronyl-thiourea compounds and medical application | |
| CN106573888A (en) | Multi-component crystals of vismodegib and selected co-crystal formers or solvents | |
| CN104610195A (en) | Aspartate of vortioxetine or hydrate thereof as well as preparation method and application thereof | |
| CN104250225A (en) | Atazanavir phosphate and its preparation method and use | |
| CN104250224A (en) | Atazanavir fumarate and its preparation method and use | |
| CN104250223A (en) | Atazanavir hydrobromide and preparation and application thereof | |
| US20130225638A1 (en) | Imidazole derivatives and preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141231 |
|
| RJ01 | Rejection of invention patent application after publication |